The judge overseeing a dispute between Kraft and Bega over peanut butter trade dress rights has stayed orders barring Kraft from selling peanut butter in Australia featuring the disputed trade dress while it appeals its loss to Bega in the case.
Maurice Blackburn has hit back at a lawsuit by State Street Global Advisors over the law firm’s use of a replica of its Fearless Girl statue, denying it has infringed the asset manager’s intellectual property.
The Copyright Tribunal erred by including rights in a reissued Foxtel licence agreement that fell outside the authority of the licence grant holder, the Phonographic Performance Company of Australia, the Full Federal Court has found.
India’s God of Cricket Sachin Tendulkar is suing Australian bat maker Spartan Sports, accusing the company of failing to pay him $2.87 million under a licensing deal and continuing to use his image after he terminated the agreement.
The long-running dispute between Kraft Foods and Bega over who owns the rights to use the signature Kraft peanut butter trade dress in Australia is not over, with Kraft appealing a ruling that found Bega had acquired the rights to the trade dress when it purchased Kraft unit Mondelez’s Australian and New Zealand business in 2017.
Airtasker has succeeded in opposing a competitor’s application to trade mark the phrase ‘Like a Boss’, which the popular gig marketplace used in a long-running ad campaign.
A subsidiary of Coca Cola has won its bid for removal of Sunraysia Natural Beverages’ Honest Kids trade mark for non-use, with IP Australia finding only “minimal and isolated” uses of the disputed mark.
Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.
In its opening submissions in a trade mark case brought by Botox maker Allergan, Australian cosmetics brand Self Care compared its used of the word Botox to describe its alternative cosmetic products to the iPhone secondary accessories market, saying its use did not imply an affiliation with the injectable wrinkle treatment’s maker.
Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step.